Serotonin Pharmacology

Correct Answer

A — Amitriptyline

Rationale

Amitriptyline is the tricyclic antidepressant used as a first-line agent for migraine prophylaxis. Valproate and topiramate are antiepileptics used for migraine prevention. Propranolol is a beta-blocker and is also first-line for migraine prophylaxis, but it is not a tricyclic antidepressant.

Correct Answer

C — Non-selective agonist at serotonin, dopamine, and adrenergic receptors

Rationale

Ergotamine is classified as a non-selective agonist at multiple receptor types — serotonin, dopamine, and adrenergic receptors. This broad receptor activity contrasts sharply with triptans, which are selective serotonin type 1B and type 1D agonists. The non-selectivity of ergotamine accounts for its wider adverse effect profile compared to triptans, including pronounced nausea from dopamine receptor activation and systemic vasoconstriction from adrenergic effects.

Correct Answer

B — Propranolol

Rationale

Propranolol is a non-selective beta-adrenergic receptor antagonist and is among the first-line agents for migraine prophylaxis, along with metoprolol. Amitriptyline is a tricyclic antidepressant. Valproate is an antiepileptic. Erenumab is a calcitonin gene-related peptide receptor monoclonal antibody — the newest class of migraine preventives.

Correct Answer

D — Topiramate

Rationale

Topiramate is an antiepileptic classified as a first-line migraine prophylactic and is specifically associated with cognitive adverse effects — word-finding difficulty and slowed thinking — that distinguish it from other preventive agents. Valproate is also an antiepileptic used for migraine prevention but is associated with teratogenicity rather than cognitive effects. Propranolol is a beta-blocker. Amitriptyline is a tricyclic antidepressant.

Correct Answer

A — Dihydroergotamine

Rationale

Dihydroergotamine is a semi-synthetic derivative of ergotamine with less vasoconstrictive potency and substantially less nausea. It is administered intravenously or intramuscularly in emergency settings for severe refractory migraine that has not responded to oral therapies. Sumatriptan and rizatriptan are triptans — selective serotonin type 1B/1D agonists — not ergot derivatives. Ergotamine is the natural ergot alkaloid parent compound from which dihydroergotamine is derived.

Correct Answer

C — Calcitonin gene-related peptide receptor monoclonal antibody

Rationale

Erenumab is classified as a calcitonin gene-related peptide receptor monoclonal antibody — it blocks the receptor for calcitonin gene-related peptide, the neuropeptide central to migraine pathophysiology. It is given as a monthly subcutaneous injection for migraine prevention and represents the newest and most mechanistically targeted class of migraine preventives. Beta-adrenergic antagonism describes propranolol. Selective serotonin type 1B/1D agonism describes the triptans. Antiepileptic classification describes valproate and topiramate.

Correct Answer

B — Serotonin type 1B receptors are expressed on coronary arteries, and triptan agonism can cause coronary vasoconstriction and myocardial ischemia

Rationale

Triptans are selective serotonin type 1B and type 1D agonists. While the intended target is serotonin type 1B receptors on meningeal vessels — causing therapeutic vasoconstriction during migraine — the same receptor subtype is expressed on coronary arteries. In patients with coronary artery disease, triptan-induced coronary vasoconstriction can precipitate myocardial ischemia. Chest tightness is a common triptan adverse effect even in patients without coronary disease, but in the presence of coronary artery disease the risk becomes clinically unacceptable. Triptans do not block calcitonin gene-related peptide receptors — that mechanism belongs to erenumab and the gepant class — so the established contraindication in coronary artery disease is specifically serotonin type 1B-mediated coronary vasoconstriction, not calcitonin gene-related peptide pathway inhibition.

Correct Answer

D — Both agents cause cranial vasoconstriction through different mechanisms, and their combination produces additive vasospasm

Rationale

Triptans produce vasoconstriction through selective serotonin type 1B agonism. Ergotamine produces vasoconstriction through non-selective agonism at serotonin, dopamine, and adrenergic receptors. Despite acting through different receptor mechanisms, both converge on the same end effect — cranial and peripheral vasoconstriction. Their combination within 24 hours produces additive vasospasm that can cause severe ischemia. Neither agent inhibits serotonin reuptake, so serotonin syndrome is not the concern. They do not compete for the same receptor — they are both agonists that produce the same vascular effect.

Correct Answer

A — Cortical spreading depression

Rationale

Cortical spreading depression — a slowly propagating wave of neuronal depolarization followed by suppression — is the current model's initiating event in migraine. It underlies the migraine aura in patients who experience it and triggers activation of the trigeminal nerve, which innervates pain-sensitive meningeal blood vessels. Activated trigeminal terminals then release calcitonin gene-related peptide and substance P at the meningeal vessel wall, producing vasodilation and neurogenic inflammation. A drop in serotonin transporter activity and chemoreceptor trigger zone activation are not established initiating events in migraine pathophysiology. Substance P from dorsal root ganglia contributes to the inflammatory cascade but is not the trigger.

Correct Answer

C — It inhibits calcitonin gene-related peptide and substance P release from trigeminal nerve terminals, reducing neurogenic inflammation

Rationale

Serotonin type 1D receptors are expressed on trigeminal nerve terminals. When triptans activate these presynaptic receptors, they inhibit the release of calcitonin gene-related peptide and substance P — the neuropeptides responsible for meningeal vasodilation and neurogenic inflammation that generate migraine pain. This peripheral neuronal mechanism complements the vascular mechanism of serotonin type 1B agonism, making dual 5-HT1B/1D agonism more effective than vascular constriction alone. Triptans do not activate raphe neurons, block serotonin type 3 receptors, or engage descending noradrenergic pathways in their antimigraine mechanism.

Correct Answer

B — Ergotamine is a potent uterotonic that stimulates uterine smooth muscle contractions, risking miscarriage or preterm delivery

Rationale

Ergot alkaloids have long been recognized as potent uterotonics — they stimulate uterine smooth muscle contraction through their adrenergic and serotonergic agonist properties. This effect was historically exploited to control postpartum hemorrhage before safer agents became available, but it makes ergotamine dangerous in pregnancy due to the risk of precipitating uterine contractions leading to miscarriage or preterm birth. Ergotamine does not inhibit fetal serotonin synthesis, does not selectively block placental blood flow through the mechanism described, and does not interact with progesterone receptors.

Correct Answer

D — Valproate is strongly teratogenic, associated with neural tube defects, developmental delay, and craniofacial abnormalities

Rationale

Valproate is one of the most teratogenic drugs in common clinical use. Fetal exposure is associated with neural tube defects, craniofacial abnormalities, and significant neurodevelopmental delay. For this reason, valproate is generally avoided in women of childbearing potential, and folic acid supplementation is recommended when it must be used. While valproate does impair folate metabolism, the primary concern is not maternal megaloblastic anemia but fetal neural tube closure failure. Valproate does not inhibit dopamine synthesis or cause uterine contractions.

Correct Answer

A — Early treatment blocks peripheral pain signals before central sensitization is established, which would otherwise render the triptan less effective

Rationale

As a migraine attack progresses, persistent pain signaling from meningeal nociceptors leads to central sensitization — amplification of pain processing at the level of the trigeminal nucleus and thalamus. Once central sensitization is established, peripheral interventions such as triptans become substantially less effective because the pain is now maintained centrally, even if the peripheral trigger is addressed. Taking a triptan early, before this central amplification occurs, allows it to block the peripheral input that would otherwise sustain the attack. While nausea can impair oral absorption, that is a secondary concern. Receptor density and calcitonin gene-related peptide release windows are not the established mechanism of the timing effect.

Correct Answer

C — Cognitive impairment including word-finding difficulty and slowed thinking

Rationale

Topiramate is associated with cognitive adverse effects — most characteristically word-finding difficulty (anomia) and slowed thinking — that some patients find disabling enough to discontinue the drug. These effects distinguish topiramate from other migraine prophylactics. Weight loss, rather than weight gain, is another topiramate effect. Sedation and weight gain are characteristic of valproate and some antidepressants. Teratogenicity is the primary concern with valproate, not topiramate. Anticholinergic effects describe amitriptyline among the prophylactic options.

Correct Answer

D — Triptans, because serotonin type 1B receptor agonism on coronary arteries can cause coronary vasoconstriction and precipitate ischemia

Rationale

Triptans are contraindicated in coronary artery disease because serotonin type 1B receptors are expressed on coronary arteries as well as meningeal vessels. Triptan-induced activation of these receptors can cause coronary vasoconstriction sufficient to precipitate myocardial ischemia in a patient with already-compromised coronary blood flow. This is the most high-yield triptan contraindication at Step 1. Non-steroidal anti-inflammatory drugs are not contraindicated in migraine for the reason described and are commonly used for mild to moderate migraine. Dopamine antagonist antiemetics do not raise myocardial oxygen demand through the mechanism described. Calcitonin gene-related peptide antibodies have a favorable cardiovascular profile and are not contraindicated in coronary artery disease by the mechanism described.

Correct Answer

B — Both ergotamine and sumatriptan cause vasoconstriction, and combining them within 24 hours produces additive vasospasm that risks ischemia

Rationale

Ergotamine causes vasoconstriction through non-selective agonism at serotonin, dopamine, and adrenergic receptors. Sumatriptan causes vasoconstriction through selective serotonin type 1B agonism. Despite acting at different receptor types, both produce the same end effect. Using both agents within 24 hours allows their vasoconstrictive effects to compound, producing additive vasospasm that can cause peripheral or cranial ischemia. A minimum 24-hour separation is required between any ergot alkaloid and any triptan, in either direction. Ergotamine does not meaningfully inhibit cytochrome P450 enzymes metabolizing sumatriptan, and the other proposed mechanisms are not established.

Correct Answer

A — Propranolol

Rationale

Propranolol is a non-selective beta-adrenergic antagonist and is considered a first-line migraine prophylactic with a comparatively favorable safety profile in pregnancy among the available options. Valproate is strongly teratogenic — associated with neural tube defects and developmental delay — and is contraindicated in pregnancy. Topiramate also carries teratogenic risks and is avoided in pregnancy when alternatives exist. Ergotamine is absolutely contraindicated in pregnancy because it is a potent uterotonic that can precipitate miscarriage or preterm labor. Among the first-line prophylactic agents, beta-blockers represent the most appropriate choice when a pregnant patient requires preventive therapy.

Correct Answer

C — Intravenous dihydroergotamine

Rationale

Dihydroergotamine is the ergot alkaloid formulated for intravenous and intramuscular administration and is used in emergency settings for severe refractory migraine that has not responded to triptans or oral therapies. It has less vasoconstrictive potency and substantially less nausea than ergotamine, making it better tolerated in this acute setting. Sumatriptan is not available as an intravenous formulation for clinical use in this context, and the patient has already failed oral sumatriptan. Intravenous valproate is used for seizures, not acute migraine in this role. Ergotamine tartrate is taken orally or sublingually for outpatient migraine — it does not have an intravenous formulation used in emergency migraine management, and dihydroergotamine is the correct ergot derivative for parenteral use.